Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Organon will receive $14.00 in cash for each share of Organon that they own. KSF is seeking to determine whether this consideration and the process that led to it.

Business Wire • 27 minutes ago

Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

KIRKLAND, Quebec & SHANGHAI--(BUSINESS WIRE)--Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA.

Business Wire • Jun 23, 2026

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Jun 22, 2026

Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon completes agreement to license MIUDELLA®, Sebela's hormone-free IUD, expanding its long-acting reversible contraception portfolio.

Business Wire • Jun 22, 2026

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

INCHEON, South Korea & KIRKLAND, Quebec--(BUSINESS WIRE)--Organon and Samsung Bioepis expand agreement to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA® (ustekinumab) in Canada.

Business Wire • Jun 18, 2026

Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19

OGN's TOFIDENCE gains FDA approval for life-threatening CRS and certain hospitalized COVID-19 patients, broadening its critical-care role.

Zacks Investment Research • Jun 12, 2026

Organon wins US approval to widen use of arthritis biosimilar drug

Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded use of its arthritis drug, ​a biosimilar to Roche's Actemra, to treat ‌a life‑threatening immune reaction in some cancer patients and COVID-19 in patients needing breathing support.

Reuters • Jun 10, 2026

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Jun 9, 2026

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 2, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Organon & Co. ("Organon" or the "Company") (NYSE - OGN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Sun Pharmaceutical Industries Limited for $14.00 per share in an all-cash transaction with an enterprise valuation of $11.75 billion. The investigation concerns whether the Organon Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

Newsfile Corp • Jun 2, 2026

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • May 29, 2026